Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL2-BIG phase II trial of bendamustine debulking followed by obinutuzumab and ibrutinib in CLL
2014-000569-35Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Oct 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine, ibrutinib and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University of Cologne. Primary endpoint: Overall response rate. Started Oct 2014; status: completed.
02
Drugs
bendamustineibrutinibobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2014-000569-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000569-35.